Advertisement

Adult Respiratory Distress Syndrome: Treatment in the Next Decade

  • R. C. Bone
Conference paper
Part of the Anaesthesiologie und Intensivmedizin / Anaesthesiology and Intensive Care Medicine book series (A+I, volume 167)

Abstract

The adult respiratory distress syndrome (ARDS) is an entity which develops when the lung is injured by a variety of processes. Such diverse insults as bacterial sepsis, aspiration, fat embolism, shock, drug injury and others are known to cause this syndrome [1, 2]. Regardless of the etiology, the damage is associated with the development of diffuse pulmonary cell injury and interstitial and alveolar edema, and inflammation [2, 3]. The syndrome is characterized by dyspnea and diffuse pulmonary infiltrates on chest roentgenogram, hypoxemia and decreased lung compliance [2–4].

Keywords

Disseminate Intravascular Coagulation Acute Respiratory Failure Tranexamic Acid Adult Respiratory Distress Syndrome Glyceryl Ether 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hudson LD (1982) Causes of the adult respiratory distress syndrome: clinical recognition. In: Bone RC (ed) The Adult Respiratory Distress Syndrome. Clin Chest Med 3(1):195–212Google Scholar
  2. 2.
    Murray JF (1977) Mechanisms of acute respiratory failure. Am Rev Respir Dis 115:1071–1078Google Scholar
  3. 3.
    Petty TL (1982) Adult respiratory distress syndrome: definition and historical perspective. In Bone RC (ed) The Adult Respiratory Distress Syndrome. Clin Chest Med 3(1):3–7Google Scholar
  4. 4.
    Pontoppidan H, Geffin B ,Lowenstein E (1972) Acute respiratory failure in the adult (first of three parts). N Engl J Med 287:690–698PubMedGoogle Scholar
  5. 5.
    Shimada Y ,Yoshiya I ,Tonaka K et al (1979) Evaluation of the progress and prognosis of adult respiratory distress syndrome: simple respiratory physiologic measurements. Chest 76:180–186PubMedGoogle Scholar
  6. 6.
    Fowler AA, Hammon RF, Good JT et al (1982) Risk with common predispositions. Intern Med 98:595–597Google Scholar
  7. 7.
    Pepe PE, Potkin RT, Holtman DH et al (1982) Clinical predictors of the adult respiratory distress syndrome. Am J Surg 144:124–130PubMedGoogle Scholar
  8. 8.
    White MK, Shepro D, Hechtman B (1973) Pulmonary function and platelet-lung interaction. J Appl Physiol 34:697–703PubMedGoogle Scholar
  9. 9.
    Radegran L, Bergentz SE, Lewis DH et al (1971) Pulmonary effects of induced platelet aggregation. Intravascular obstruction or vasoconstriction. Scand J Clin Lab Invest 28:423–427PubMedGoogle Scholar
  10. 10.
    Evans G, Mustard JF (1968) Inhibition of the platelet-surface reaction in endotoxin shock and the generalized Schwartzman reaction. J Clin Invest 47:31aGoogle Scholar
  11. 11.
    Stein M, Thomas DP (1967) Role of platelets in the acute pulmonary responses to endotoxin. J Appl Physiol 23:47–52PubMedGoogle Scholar
  12. 12.
    Brigham KL (1982) Mechanisms of lung injury. In: Bone RC (ed) The Adult Respiratory Distress Syndrome. Clin Chest Med 3(1):9–24Google Scholar
  13. 13.
    Demling RH (1980) The pathogenesis of respiratory failure after trauma and sepsis. Surg Clin NA 60(6):1373–1390Google Scholar
  14. 14.
    Hohn DC, Meyers AJ, Gherine ST et al (1980) Production of acute pulmonary injury by leukocytes and activated complement. Surg 88:49–57Google Scholar
  15. 15.
    Hyman A, Sponnhale E, Kadowitz P (1978) Prostaglandins and the lung. In: Lung Disease: State of the Art 1977-1978. American Lung Association, New York, pp 229–254Google Scholar
  16. 16.
    Jacobs ER, Soulsby ME ,Bone RC et al (1982) Ibuprofen in canine endotoxin shock. J Clin Invest 70:536–541PubMedGoogle Scholar
  17. 17.
    Bone RC, Francis PB, Pierce AK (1976) Intravascular coagulation associated with the adult respiratory distress syndrome. Am J Med 61:585–590PubMedGoogle Scholar
  18. 18.
    Van Dorp DA (1967) Aspects of the biosynthesis of prostaglandins. Prog Biochem Pharm 3:71–82Google Scholar
  19. 19.
    Samuelson B (1967) Biosynthesis and metabolism of prostaglandins. Biochem Pharm 3:59–70Google Scholar
  20. 20.
    Ramwell RW,Shaw JE (1970) Biological significance of the prostaglandins. Recent Prog Horm Res 26:139–187PubMedGoogle Scholar
  21. 21.
    Bertstrom S, Dressier F, Krabisch L et al (1962) The isolation and structure of a smooth muscle stimulating factor in normal sheep and pig lungs: prostaglandin and related factors. Arkh Kemi 63–66Google Scholar
  22. 22.
    Anggard E (1965) The isolation and determination of prostaglandins in lungs of sheep ,guinea pig, monkey and man. Biochem Pharm 14:1507–1516PubMedGoogle Scholar
  23. 23.
    Mathe AA (1976) Studies on actions of prostaglandins in the lung. Acta Physiol Scand 441:1–55Google Scholar
  24. 24.
    Cuthbert MF (1973) Prostaglandins and respiratory smooth muscle. In: Cuthbert MF (ed) The Prostaglandins. Lippincott, Philadelphia ,pp 253–285Google Scholar
  25. 25.
    Samuelsson B, Franstrom E, Green K et al (1971) Metabolism of prostaglandins. Ann Ny Acad Sci 180:138–161Google Scholar
  26. 26.
    Kadowitz PJ, Joiner PD, Hyman AL (1975) Physiological and pharmacological roles of prostaglandins. Am Rev Pharm 15:285–305Google Scholar
  27. 27.
    Leslie CA, Levine L (1973) Evidence for the presence of a prostaglandin E2-9-keto reductase in rat organs. Biochem Biophys Res Commun 52:717–724PubMedGoogle Scholar
  28. 28.
    Zurier RB (1974) In: Weissman G (ed) Mediators of inflammation. Plenum Press, New York, p. 163Google Scholar
  29. 29.
    Waldker JR, Smith MJH ,Ford-Hutchinson AW (1976) Prostaglandins and leukotaxis. J Pharm Pharmacol 28:745–747Google Scholar
  30. 30.
    Fletcher JR ,Ramwell PW (1980) Prostaglandins in shock: to give or block. Adv Shock Res 3:57–66PubMedGoogle Scholar
  31. 31.
    Fletcher JR ,Ramwell PW ,Harris RH (1980) Thromboxane ,prostacyclin and hemodynamic events in primate endotoxin shock. Adv Shock Res 3:145–148Google Scholar
  32. 32.
    Wise WC ,Cook JA ,Halushka PV (1981) Implications for thromboxane A2 in the pathogenesis of endotoxic shock. Adv Shock Res 6:83–91PubMedGoogle Scholar
  33. 33.
    Webb PJ ,Westwick J ,Scully MF et al (1981) Do prostacyclin and thromboxane play a role in endotoxic shock. Br J Surg 68:720–724PubMedGoogle Scholar
  34. 34.
    Bowers RE, Ellis EF, Brigham KL et al (1979) Effects of prostaglandin cyclic endoperoxides on the lung circulation of unanesthetized sheep. J Clin Invest 62:131–137Google Scholar
  35. 35.
    Demling RH, Smith M, Gunther R et al (1981) The effect of prostacyclin infusion on endotoxin-induced lung injury. Surg 89(2):257–263Google Scholar
  36. 36.
    Demling RH, Smith M, Gunther R et al (1981) Pulmonary injury and prostaglandin production during endotoxemia in conscious sheep. Am J Physiol 240:H348–H353PubMedGoogle Scholar
  37. 37.
    Traker DL, Adair TH, Adams T Jr (1981) Hemodynamic consequences of endotoxemia in sheep. Circ Shock 8:551–561Google Scholar
  38. 38.
    Marx JL (1982) The leukotrienes in allergy and inflammation. Science 215:1380–1383PubMedGoogle Scholar
  39. 39.
    Samuelsson B, Borgedt P, Hammarstrom et al (1980) Leukotrienes: a new group of biologically acting compounds. Adv Prostaglandins Thromboxane Res 6:1–17Google Scholar
  40. 40.
    Chand N (1979) FPL 55712 - an antagonist of slow reacting substance of anaphylaxis (SRS-A): a review. Agents and Actions 9:133–140PubMedGoogle Scholar
  41. 41.
    Weiso JW, Drazen JM, Coles N (1982) Bronchoconstrictor effects of leukotriene C in humans. Science 216:196–198Google Scholar
  42. 42.
    Brocklehurst WE (1962) Slow-reacting substance and related compounds. Progr Allergy 6:539–558Google Scholar
  43. 43.
    Wasserman SI ,Goetzl EJ ,Austen KF (1975) Inactivation of slow-reacting substance of anaphylaxis by human eosinophil arylsulfatase. J Immunol 114:645–649PubMedGoogle Scholar
  44. 44.
    Brocklehurst WE (1960) The release of histamine and formation of a slow-reacting substance (SRS-A) during anaphylactic shock. J Physiol 151:416–435PubMedGoogle Scholar
  45. 45.
    Orange RP ,Stechschulte DJ ,Austen FK (1969) Cellular mechanisms involved in the release of slow-reacting substance of anaphylaxis. Fed Proc 28:1710–1715PubMedGoogle Scholar
  46. 46.
    Spector WG ,Willoughby DA (1968) The pharmacology of inflammation. Grune and Stratton ,New YorkGoogle Scholar
  47. 47.
    Smith M ,Gunther R ,Zaiac C et al (1981) Pulmonary microvascular injury from lipoxygenase infusion: comparison with endotoxemia. Circ Shock 8:647–652PubMedGoogle Scholar
  48. 48.
    Brigham K ,Bowers R, Mc Keen C (1981) Methylprednisolone prevention of increased lung vascular permeability following endotoxemia in sheep. J Clin Invest 67:1103–1108PubMedGoogle Scholar
  49. 49.
    Maron MB (1982) Differential effects of histamine on protein permeability in dog lung and forelimb. Am J Physiol 242:H656Google Scholar
  50. 50.
    Brigham K (1975) Effects of histamine on lung transvascular fluid and protein movement in awake sheep. Chest 67:508Google Scholar
  51. 51.
    Bone RC, Lerner S, Murphy EM et al (1979) Vasoactive medication in the pathogenesis of experimental adult respiratory distress syndrome. Chest 75:218–220PubMedGoogle Scholar
  52. 52.
    Lemaire I ,Tseng R, Lemaire S (1978) Systemic administration of β-endorphin: potent hypotensive effect involving a serotonergic pathway. Proc Natl Acad Sci USA 75:6240:6242PubMedGoogle Scholar
  53. 53.
    Holaday JW, Faden AI (1978) Naloxone reversal of endotoxin hypotension suggests role of endorphins in shock. Nature 275:450–451PubMedGoogle Scholar
  54. 54.
    Faden AI, Holaday JW (1980) Experimental endotoxin shock: the pathopysiologic function of endorphins and treatment with opiate antagonists. J Infect Dis 142:229–237PubMedGoogle Scholar
  55. 55.
    Janssen HF, Lutherer LO (1980) Ventriculocisternal administration of naloxone protects against severe hypotension during endotoxin shock. Brain Res 193:608–612Google Scholar
  56. 56.
    Reynolds DG, Gurll NJ, Vargish T et al (1980) Blockade of opiate receptors with naloxone improves survival and cardiac performance of canine endotoxic shock. Circ shock 7:38–49Google Scholar
  57. 57.
    Peters WP, Johnson MW, Friedman PA et al (1981) Pressor effect of naloxone in septic shock. Lancet 529–532Google Scholar
  58. 58.
    Bone RC, Jacobs ER, Potter DM et al (1981) Endorphins in endotoxin shock. Microcirc 1(3):285–295Google Scholar
  59. 59.
    Henson PM, Cochrane CG (1975) The effect of complement depletion on experimental tissue injury. Ann NY Acad Sci 256:426–440PubMedGoogle Scholar
  60. 60.
    Cochrane CG, Vannue ER, Dixon FJ (1965) A role of polymorphonuclear leukocytes and complement in neutrotoxic nephritis. S Exp Med 112:99–116Google Scholar
  61. 61.
    da Sliva WD, Eisele JW, Lepow IH (1967) Complement as a mediator of inflammation. J Exp Med 126:1027–1084Google Scholar
  62. 62.
    Brigham KL, Woolverton WC, Blake LH et al (1974) Increased vascular permeability caused by Pseudomonas bacteremia. J Clin Invest 54:792–804PubMedGoogle Scholar
  63. 63.
    Craddock PR, Frehr J, Brigham KL et al (1977) Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis. N Engl J Med 296:769–774PubMedGoogle Scholar
  64. 64.
    Webster RO, Larsen GL, Mitchell BC et al (1982) Absence of inflammatory lung injury in rabbits challenged intravascullary with complement-derived chemotactic factors. Am Rev Respir Dis 125:335PubMedGoogle Scholar
  65. 65.
    Jose PJ, Forrest MJ, Williams TJ (1981) Human C5a des Arg increases vascular permeability. J Immunl 127:2376Google Scholar
  66. 66.
    Johnson A, Malik AB (1980) Effect of granulocytopenia on extravascular lung water content after microembolization. Am Rev Respir Dis 122:561–568PubMedGoogle Scholar
  67. 67.
    Walker RI, Fletcher JR (1981) Possible contribution of platelets to the pathophysiological effects of endotoxins at the cellular level. In: Pathophysiological Effects of Endotoxins at the Cellular Level. Alan R Liss, Inc, New York, pp 173–185Google Scholar
  68. 68.
    Vaage J (1980) The role of platelets in posttraumatic pulmonary insufficiency. Acta Chim Scand Suppl 499:141–158Google Scholar
  69. 69.
    Murphy TL, Allison RC, Weisman IM et al (1981) Role of platelet serotonin in the canine pulmonary response to endotoxin. J Appl Physiol 50:178–184PubMedGoogle Scholar
  70. 70.
    Packham NA, Nishizawa EE, Mustard JF (1968) Response of platelets to tissue injury. Biochem Pharmacol 171:84Google Scholar
  71. 71.
    Wesler BB, Coupal E (1973) Platelet-dependent generation of chemotactic activity in serum. J Exp Med 137:1419–1430Google Scholar
  72. 72.
    Humphrey DM, McManus LM, Sataouchi K et al (1982) Vasoactive properties of acute glyceryl ether phosphorcholine and analogues. Lab Invest 46:422–428PubMedGoogle Scholar
  73. 73.
    Minna JD, Robboy SJ, Coleman RW (1974) Disseminated intravascular coagulation in man. Charles C Thomas, Springfield, pp 26–34Google Scholar
  74. 74.
    Merskey C (1976) Defibrination syndrome. In: Biggs R (ed) Human Blood Coagulation, Haemostasis and Thrombosis. Blackwell Scientific Publications, Oxford, pp 92–536Google Scholar
  75. 75.
    Robboy SJ, Colman RW, Minna JD (1972) Pathology of disseminated intravascular coagulation (DIC): Analysis of 26 cases. Human Path 3:327–340Google Scholar
  76. 76.
    Lindquist O, Rammer L, Saldeen T (1972) Pulmonary insufficiency and fibrinolysis inhibition in posttraumatic autopsy material. Acta Chir Scand 138:545–549PubMedGoogle Scholar
  77. 77.
    Schneider RC, Zapol WM, Carvalho AC (1980) Platelet consumption and sequestration in severe acute respiratory failure. Am Rev Respir Dis 122:445–451PubMedGoogle Scholar
  78. 78.
    Saldeen T (1976) The microembolism syndrome. Microvasc Res 11:227–259PubMedGoogle Scholar
  79. 79.
    Greene R, Zapol W, Schneider M et al (1981) Early bedside detection of pulmonary vascular occlusion during respiratory failure. Am Rev Respir Dis 124:593–601PubMedGoogle Scholar
  80. 80.
    Saldeen T (1977) The microembolism syndrome. Thromb Haemost 38:275Google Scholar
  81. 81.
    Curreri PW, Wilterdin ME, Baxter CR (1975) Coagulation dynamics following thermal injury. Ann Surg 181:161–164PubMedGoogle Scholar
  82. 82.
    Satterwhite TK, Harviger J, Bruklow SL et al (1973) Degradation products of fibrinogen and fibrin in bacteremia due to gram-negative rods. J Infect Dis 127:437–442PubMedGoogle Scholar
  83. 83.
    Curreri PW, Wilterdink ME, Baxter CR (1975) Characterization of elevated fibrin split products following thermal injury. Ann Surg 181:157–161PubMedGoogle Scholar
  84. 84.
    Haynes JB, Hyers TM, Giclas PC et al (1980) Elevated fibrinogen degradation products in adult respiratory distress syndrome. Am Rev Respir Dis 122:841–847PubMedGoogle Scholar
  85. 85.
    Holcroft JW, Blaisdell FW, Trunkey DD et al (1977) Intravascular coagulation and pulmonary edema in the septic baboon. J Surg Res 22:209–220PubMedGoogle Scholar
  86. 86.
    Malik AB, Hoyte VZ (1977) Time course of pulmonary vascular response to micro embolization. J Appl Physiol 43:51–58PubMedGoogle Scholar
  87. 87.
    Arfors KE, Busch C, Jakobson S et al (1972) Pulmonary insufficiency following intravenous infusion of thrombin and AMCA (tranexamic acid) in the dog. Acta Chir Scand 138:445–452PubMedGoogle Scholar
  88. 88.
    Staub NC, Ohkuda K, Nakahara K et al (1977) Effects of microemboli on lung fluid balance in anaesthetized sheep. Chest Suppl 71:301–302Google Scholar
  89. 89.
    Binder AS, Nakahara K, Ohkuda K et al (1979) Effect of heparin on fibrinogen depletion on lung fluid balance in sheep after emboli. J Appl Physiol 47:213–219PubMedGoogle Scholar
  90. 90.
    Binder AS, Kageler W, Perel A et al (1980) Effect of platelet depletion on lung vascular permeability after microemboli in sheep. J Appl Physiol 48:414–420PubMedGoogle Scholar
  91. 91.
    Ratnoff OD (1966) The effect of human plasmin upon cutaneous vascular permeability. Thromb Diast Haemorrh 20:210–215Google Scholar
  92. 92.
    Bucko W, de Gaetano G, Franco R et al (1976) Biological properties of dialysable peptides derived from plasmin digestion of bovine fibrinogen preparations. Thromb Haemost 35:651–658Google Scholar
  93. 93.
    Belew M, Gerdin B, Lindeberg G et al (1980) Structure activity relationships of vasoactive peptides derived from fibrin or fibrinogen degraded by plasmin. Biochem Biophys Acta 621:169–178PubMedGoogle Scholar
  94. 94.
    Gerdin B, Saldeen T (1978) Effect of fibrin degradation products on microvascular permeability. Thromb Res 13:995–1006PubMedGoogle Scholar
  95. 95.
    Busch C, Gerdin B (1981) Effect of low molecular weight fibrin degradation products on endothelial cells in culture. Thromb Res 22:33–39PubMedGoogle Scholar
  96. 96.
    Manwaring D, Curreri PW (1980) The role of platelet aggregation and release in fragment D-induced pulmonary dysfunction. Ann Surg 192:103–107PubMedGoogle Scholar
  97. 97.
    Manwaring D, Curreri PW (1980) Platelet mediation of fragment D-induced respiratory distress syndrome. Surg Forum 31:242–243Google Scholar
  98. 98.
    Manwaring D, Curreri PW (1982) Platelet and neutrophil sequestration after fragment D-induced respiratory distress. Cir Shock 9:75–80Google Scholar
  99. 99.
    Odom H, York FC, Hiller FC et al (1982) Fibrin degradation product D in endotoxin shock. Microcirc 2(1):91–98Google Scholar
  100. 100.
    Hopper KE, Geczy CL, Dovier WA (1981) A mechanism of migration inhibition in delayed-type hypersensitivity reactions. I. Fibrin deposition on the surfaces of alveolar macrophages in vivo. J Immunol 126:1052–1058PubMedGoogle Scholar
  101. 101.
    Geczy CL, Hopper KE (1981) A mechanism of migration inhibition in delayed-type hypersensitivity reactions. II. Lymphokines promote procoagulant activity of macrophages in vitro. J Immunol 126:105–1065Google Scholar
  102. 102.
    Hocking WG, Golde DW (1979) The pulmonary alveolar macrophage. N Engl J Med 301:639–645PubMedGoogle Scholar
  103. 103.
    Rennhard SL, Crystal RG (1981) Fibronectin in human bronchopulmonary lavage fluid: elevation in patients with interstitial lung disease. J Clin Invest 69:113–122Google Scholar
  104. 104.
    Chapman HA Jr, Veurin Z, Hibbs JB Jr (1982) Macrophage fibrinolytic activity: identification of two pathways of plasmin formation by intact cells and of a plasminogen activator inhibitor. Cell 28:653–662PubMedGoogle Scholar
  105. 105.
    Saha TM, Jaffe E (1980) Plasma fìbronectin (opsonic glycoprotein): H2 synthesis by vascular endothelial cells and role in cardiopulmonary integrity after trauma as related to reticuloendothelial function. Am J Med 68:577Google Scholar
  106. 106.
    Teplitz C (1976) The case pathology and integrated medical science of adult acute respiratory insufficiency . Surg Clin N Med 56:1091–1100Google Scholar
  107. 107.
    Bachofen M, Weibel ER (1977) Alteration of the gas exchange apparatus in adult respiratory insufficiency associated with septicemia. Am Rev Respir Dis 116:589–599PubMedGoogle Scholar
  108. 108.
    Lamy M, Fallat RJ, Koeninger E et al (1976) Pathological features and mechanisms of hypoxemia in adult respiratory distress syndrome. Am Rev Respir Dis 114:267–277PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1984

Authors and Affiliations

  • R. C. Bone

There are no affiliations available

Personalised recommendations